Jump to main content
Jump to site search

Issue 14, 2018
Previous Article Next Article

An enzymatic advance in nicotine cessation therapy

Author affiliations

Abstract

A nicotine-degrading enzyme termed NicA2 was altered (NicA2-J1) through fusion of an albumin binding domain to increase its half-life. Examination of NicA2-J1 in vivo demonstrated a complete blockade of brain nicotine access, which in turn blunted nicotine's psychoactive effects. These data further support development of pharmacokinetic nicotine cessation therapeutics.

Graphical abstract: An enzymatic advance in nicotine cessation therapy

Back to tab navigation

Supplementary files

Publication details

The article was received on 28 Nov 2017, accepted on 28 Dec 2017 and first published on 02 Jan 2018


Article type: Communication
DOI: 10.1039/C7CC09134F
Citation: Chem. Commun., 2018,54, 1686-1689
  •   Request permissions

    An enzymatic advance in nicotine cessation therapy

    S. Xue, M. Kallupi, B. Zhou, L. C. Smith, P. O. Miranda, O. George and K. D. Janda, Chem. Commun., 2018, 54, 1686
    DOI: 10.1039/C7CC09134F

Search articles by author

Spotlight

Advertisements